First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
"Our recent performance underscores the growing demand for innovative treatments in opioid dependence."
Moat: Orexo's competitive advantage lies in its proprietary formulation of Zubsolv, which offers better patient compliance.
growth - Investors are likely attracted to the potential for revenue growth from Zubsolv and future product developments.
Minimal - Orexo's operations are not significantly impacted by interest rates, but higher rates could affect overall healthcare spending.
Watch on earnings: Zubsolv sales growth rate, Operating cash flow margin, Market share in opioid dependence treatments.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $26M to $27M as zubsolv's market share increased by 15% in q2 2026, indicating strong demand and potential for revenue growth.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.